(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.74%) $83.23
(-1.16%) $1.619
(-0.11%) $2 344.70
(-0.16%) $27.49
(0.40%) $925.80
(-0.11%) $0.934
(-0.05%) $11.02
(-0.17%) $0.799
(0.00%) $92.17
Quarter results tomorrow
(bmo 2024-04-30)
Expected move: +/- 4.51%
Live Chart Being Loaded With Signals
Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe...
Stats | |
---|---|
本日の出来高 | 5.64M |
平均出来高 | 3.20M |
時価総額 | 159.86M |
EPS | £0 ( 2024-04-22 ) |
次の収益日 | ( £0 ) 2024-04-30 |
Last Dividend | £0 ( N/A ) |
Next Dividend | £0 ( N/A ) |
P/E | -3.05 |
ATR14 | £0.191 (0.39%) |
ボリューム 相関
Avacta Group PLC 相関
10 最も正の相関 | |
---|---|
TEM.L | 0.92 |
JAGI.L | 0.92 |
XMMS.L | 0.893 |
FCSS.L | 0.889 |
HSXJ.L | 0.885 |
EMIM.L | 0.885 |
JMG.L | 0.883 |
FEMS.L | 0.88 |
AEMD.L | 0.876 |
LAND.L | 0.875 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Avacta Group PLC 相関 - 通貨/商品
Avacta Group PLC 財務諸表
Annual | 2022 |
収益: | £9.65M |
総利益: | £4.23M (43.83 %) |
EPS: | £-0.150 |
FY | 2022 |
収益: | £9.65M |
総利益: | £4.23M (43.83 %) |
EPS: | £-0.150 |
FY | 2021 |
収益: | £2.94M |
総利益: | £2.02M (68.58 %) |
EPS: | £-0.106 |
FY | 2020 |
収益: | £3.64M |
総利益: | £2.18M (59.98 %) |
EPS: | £-0.0837 |
Financial Reports:
No articles found.
Avacta Group PLC
Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。